Pasireotide

Pasireotide

File:Pasireotide.svg
Clinical data
Synonyms	SOM230
ATC code	H01CB05 (WHO)
Legal status
Legal status	Investigational
Identifiers
IUPAC name [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
CAS Number	396091-73-9 Y
PubChem CID	9941444
UNII	98H1T17066
KEGG	D10147 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C58H66N10O9
Molar mass	1107.26 g/mol
(verify)

WikiDoc Resources for Pasireotide
Articles
Most recent articles on Pasireotide Most cited articles on Pasireotide Review articles on Pasireotide Articles on Pasireotide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Pasireotide Images of Pasireotide Photos of Pasireotide Podcasts & MP3s on Pasireotide Videos on Pasireotide
Evidence Based Medicine
Cochrane Collaboration on Pasireotide Bandolier on Pasireotide TRIP on Pasireotide
Clinical Trials
Ongoing Trials on Pasireotide at Clinical Trials.gov Trial results on Pasireotide Clinical Trials on Pasireotide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pasireotide NICE Guidance on Pasireotide NHS PRODIGY Guidance FDA on Pasireotide CDC on Pasireotide
Books
Books on Pasireotide
News
Pasireotide in the news Be alerted to news on Pasireotide News trends on Pasireotide
Commentary
Blogs on Pasireotide
Definitions
Definitions of Pasireotide
Patient Resources / Community
Patient resources on Pasireotide Discussion groups on Pasireotide Patient Handouts on Pasireotide Directions to Hospitals Treating Pasireotide Risk calculators and risk factors for Pasireotide
Healthcare Provider Resources
Symptoms of Pasireotide Causes & Risk Factors for Pasireotide Diagnostic studies for Pasireotide Treatment of Pasireotide
Continuing Medical Education (CME)
CME Programs on Pasireotide
International
Pasireotide en Espanol Pasireotide en Francais
Business
Pasireotide in the Marketplace Patents on Pasireotide
Experimental / Informatics
List of terms related to Pasireotide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pasireotide (SOM230) is an orphan drug approved in Europe for the treatment of Cushing's disease. It was developed by Novartis. Pasireotide is a somatostatin analog which has a 40-fold increased affinity to somatostatin receptor 5 than other somatostatin analogs.

The drug showed therapeutical potential in a recent study (PASPORT-CUSHINGS B2305) where 162 patients were treated with either 2x 600 µg or 2x 900 µg pasireotide s.c. daily. The effectiveness of the treatment was checked by the UFC-value (urinary free cortisol) after six months of treatment. The mean reduction of UFC after six months was 47.9%, which also lead to amelioration of clinical symptoms such as blood pressure, cholesterol value, and weight loss.

References

Template:Systemic-hormonal-drug-stub